Article

Harnessing the Power of Antibodies to Fight Bone Metastasis

2021-02-20

Abstract excerpt

Over the past 20 years, antibody-based therapies have proved to be of great value in cancer treatment. Despite the clinical success of these biopharmaceuticals, reaching targets in the bone micro-environment has proved to be difficult perhaps due to the relatively low vascularization of bone tissue and the presence of physical barriers that impair drug penetration. Here, we have used an innovative bone targeting (...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2d7f7e55-832a-5429-a92c-df23ffb0bd4d
DOI: 10.1101/2021.02.19.432037

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Harnessing the Power of Antibodies to Fight Bone MetastasisDOI 10.1101/2021.02.19.432037Read

Theranostics of Bone Metastases: The Role and Prospects of Bisphosphonate RadiopharmaceuticalsSemantic proximity Read

Biomarker-Driven Approaches to Bone Metastases: From Molecular Mechanisms to Clinical ApplicationsSemantic proximity Read

Exploring bone-tumor interactions through 3D in vitro models: Implications for primary and metastatic cancersSemantic proximity Read

Nanoparticle STING Agonist Reprograms the Bone Marrow to an Antitumor Phenotype and Protects Against Bone Destruction.Semantic proximity Read

Fibronectin as target for tumor therapySemantic proximity Read

Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.Semantic proximity Read

Tissue-Engineered Bone Serves as a Target for Metastasis of Human Breast Cancer in a Mouse ModelSemantic proximity Read

Bispecific antibody conjugates in therapeuticsSemantic proximity Read

iRGD-liposomes enhance tumor delivery and therapeutic efficacy of antisense oligonucleotide drugs against primary prostate cancer and bone metastasisSemantic proximity Read

Bortezomib Alone or in Combination with the Histone Deacetylase Inhibitor JNJ-26481585: Effect on Myeloma Bone Disease in the 5T2MM Murine Model of MyelomaSemantic proximity Read

Interference with the Microenvironmental Support Impairs the <i>De novo</i> Formation of Bone Metastases <i>In vivo</i>Semantic proximity Read

Bone morphogenetic protein 4 gene therapy in mice inhibits myeloma tumor growth, but has a negative impact on boneSemantic proximity Read